Drug Safety

, Volume 34, Issue 6, pp 449–463 | Cite as

A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery

Review Article

Abstract

Dabigatran etexilate is a novel orally administered anticoagulant that exerts its action through reversible direct thrombin inhibition. This anticoagulant has been approved for prophylaxis against venous thromboembolism (VTE) after hip or knee arthroplasty, and in a few countries also for atrial fibrillation. This article reviews the efficacy and safety of dabigatran for the prophylaxis of VTE-indication compared with data on the most common current regimen with low-molecular-weight heparin (LMWH), specifically enoxaparin.

Alternative prophylactic agents are also discussed. The results regarding efficacy and safety are very similar for dabigatran and LMWH. Bleeding and gastrointestinal reactions are the most frequently reported adverse events with a comparable incidence on LMWH and are probably the result of surgery and anaesthaesia. No adverse event that is specific for dabigatran has been observed in these studies, although dyspepsia has been reported as significantly more frequent than warfarin in long-term studies on other indications. The fact that dabigatran has no antidote has so far not been a problem in patients undergoing orthopaedic surgery. The use of the lower dose of dabigatran (150 mg) appears beneficial to reduce the risk of bleeding in patients over 75 years of age and in those with moderate renal impairment to avoid drug accumulation. The convenience of oral administration is an advantage for dabigatran over LMWH, particularly for extended prophylaxis up to 1 month after surgery. In conclusion, the benefit-risk profile of dabigatran is favourable for use as prophylaxis against VTE after major orthopaedic surgery with its convenient oral administration without need for laboratory monitoring and a low risk of bleeding or other adverse events.

References

  1. 1.
    Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009 Aug; 86(2): 139–46PubMedCrossRefGoogle Scholar
  2. 2.
    Stangier J, Rathgen K, Stahle H, et al. The pharmaco-kinetics, pharmacodynamics and tolerability of dabiga-tran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 Sep; 64(3): 292–303PubMedCrossRefGoogle Scholar
  3. 3.
    EMEA. Public assessment report for Pradaxa, 2008 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf [Accessed 2011 Apr 1]
  4. 4.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 Sep 17; 361(12): 1139–51PubMedCrossRefGoogle Scholar
  5. 5.
    Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous throm-boembolism. N Engl J Med 2009 Dec 10; 361(24): 2342–52PubMedCrossRefGoogle Scholar
  6. 6.
    AAOS. American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. Adopted by the American Academy of Orthopedic Surgeons Board of Directors May 2007 [online]. Available from URL: http://www.aaos.org/research/guidelines/PE_guideline.pdf [Accessed 2010 May 1]
  7. 7.
    Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008 Jun; 133 (6 Suppl.): 381S–453SPubMedCrossRefGoogle Scholar
  8. 8.
    Haddad FS, Kerry RM, McEwen JA, et al. Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: a possible source of variation in reported patient outcomes. J Arthroplasty 2001 Jan; 16(1): 37–46PubMedCrossRefGoogle Scholar
  9. 9.
    Freedman KB, Brookenthal KR, Fitzgerald Jr RH, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 2000 Jul; 82-A(7): 929–38PubMedGoogle Scholar
  10. 10.
    Brookenthal KR, Freedman KB, Lotke PA, et al. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001 Apr; 16(3): 293–300PubMedCrossRefGoogle Scholar
  11. 11.
    Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 338S–400SPubMedCrossRefGoogle Scholar
  12. 12.
    Kim YH, Oh SH, Kim JS. Incidence and natural history of deep-vein thrombosis after total hip arthroplasty: a prospective and randomised clinical study. J Bone Joint Surg Br 2003 Jul; 85(5): 661–5PubMedGoogle Scholar
  13. 13.
    Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007 Jul; 5(7): 1438–43PubMedCrossRefGoogle Scholar
  14. 14.
    Seagroatt V, Tan HS, Goldacre M, et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 1991 Dec 7; 303(6815): 1431–5PubMedCrossRefGoogle Scholar
  15. 15.
    Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007 Jul 23; 167(14): 1471–5PubMedCrossRefGoogle Scholar
  16. 16.
    Bjornara BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006 Mar; 88(3): 386–91PubMedCrossRefGoogle Scholar
  17. 17.
    Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353(9159): 1167–73PubMedCrossRefGoogle Scholar
  18. 18.
    Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003 Jun 17; 107 (23 Suppl. 1): I9–16PubMedCrossRefGoogle Scholar
  19. 19.
    Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia: an epide-miological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost 2005 Dec; 3(12): 2664–70PubMedCrossRefGoogle Scholar
  20. 20.
    Leizorovicz A. Epidemiology of post-operative venous thromboembolism in Asian patients: results of the SMART venography study. Haematologica 2007 Sep; 92(9): 1194–200PubMedCrossRefGoogle Scholar
  21. 21.
    Nicolaides AN, Kakkar VV, Field ES, et al. The origin of deep vein thrombosis: a venographic study. Br J Radiol 1971 Sep; 44(525): 653–63PubMedCrossRefGoogle Scholar
  22. 22.
    Kakkar VV, Howe CT, Flanc C, et al. Natural history of postoperative deep-vein thrombosis. Lancet 1969 Aug 2; 2(7614): 230–2PubMedCrossRefGoogle Scholar
  23. 23.
    Moser KM, Fedullo PF, LitteJohn JK, et al. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994 Jan 19; 271(3): 223–5PubMedCrossRefGoogle Scholar
  24. 24.
    Nielsen HK, Husted SE, Krusell LR, et al. Silent pulmonary embolism in patients with deep venous thrombosis: incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med 1994 May; 235(5): 457–61PubMedCrossRefGoogle Scholar
  25. 25.
    Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989 Mar; 95(3): 498–502PubMedCrossRefGoogle Scholar
  26. 26.
    Dorfman GS, Cronan JJ, Tupper TB, et al. Occult pulmonary embolism: a common occurrence in deep venous thrombosis. AJR Am J Roentgenol 1987 Feb; 148(2): 263–6PubMedGoogle Scholar
  27. 27.
    Williams JW, Britt LG, Eades T, et al. Pulmonary embolism after amputation of the lower extremity. Surg Gynecol Obstet 1975 Feb; 140(2): 246–8PubMedGoogle Scholar
  28. 28.
    Cruickshank MK, Levine MN, Hirsh J, et al. An evaluation of impedance plethysmography and 125I-fibrinogen leg scanning in patients following hip surgery. Thromb Haemost 1989 Nov 24; 62(3): 830–4PubMedGoogle Scholar
  29. 29.
    Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 2001 Mar; 83-A(3): 336–45PubMedGoogle Scholar
  30. 30.
    Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004 Jan 12; 164(1): 17–26PubMedCrossRefGoogle Scholar
  31. 31.
    Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004 May 27; 350(22): 2257–64PubMedCrossRefGoogle Scholar
  32. 32.
    Lieberman JR, Hsu WK. Prevention of venous thrombo-embolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 2005 Sep; 87(9): 2097–112PubMedCrossRefGoogle Scholar
  33. 33.
    Dahl OE, Caprini JA, Colwell Jr CW, et al. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost 2005 May; 93(5): 860–6PubMedGoogle Scholar
  34. 34.
    Warwick D. New concepts in orthopaedic thrombopro-phylaxis. J Bone Joint Surg Br 2004 Aug; 86(6): 788–92PubMedCrossRefGoogle Scholar
  35. 35.
    National Institutes of Health. Prevention of venous thrombosis and pulmonary embolism. Natl Inst Health Consens Dev Conf Consens Statement 1986; 6(2): 1–8Google Scholar
  36. 36.
    Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006 Nov; 452: 175–80PubMedCrossRefGoogle Scholar
  37. 37.
    Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 2005 Dec; 87(12): 1675–80PubMedCrossRefGoogle Scholar
  38. 38.
    Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002 Sep 9; 162(16): 1833–40PubMedCrossRefGoogle Scholar
  39. 39.
    Lieberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am 1997 Mar; 79(3): 319–25PubMedGoogle Scholar
  40. 40.
    Lieberman JR, Sung R, Dorey F, et al. Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty. J Arthroplasty 1997 Feb; 12(2): 180–4PubMedCrossRefGoogle Scholar
  41. 41.
    Pellegrini Jr VD, Donaldson CT, Farber DC, et al. The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res 2005 Dec; 441: 56–62PubMedCrossRefGoogle Scholar
  42. 42.
    Pellegrini Jr VD, Donaldson CT, Farber DC, et al. The Mark Coventry Award: prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006 Nov; 452: 21–7PubMedCrossRefGoogle Scholar
  43. 43.
    Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 2007 Feb; 45(2): 335–41PubMedCrossRefGoogle Scholar
  44. 44.
    White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003 Sep; 90(3): 446–55PubMedGoogle Scholar
  45. 45.
    Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. J Bone Joint Surg Br 1997 Sep; 79(5): 780–6PubMedCrossRefGoogle Scholar
  46. 46.
    Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohortstudy of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 1998 Apr 27; 158(8): 873–8PubMedCrossRefGoogle Scholar
  47. 47.
    Colwell Jr CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999 Jul; 81(7): 932–40PubMedGoogle Scholar
  48. 48.
    Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand 2000 Feb; 71(1): 47–50PubMedCrossRefGoogle Scholar
  49. 49.
    Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000 Jun 6; 132(11): 853–61PubMedGoogle Scholar
  50. 50.
    Anderson DR, Wilson SJ, Blundell J, et al. Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty. J Bone Joint Surg Am 2002 Nov; 84-A(11): 1992–7PubMedGoogle Scholar
  51. 51.
    Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perio-perative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988 May 5; 318(18): 1162–73PubMedCrossRefGoogle Scholar
  52. 52.
    Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991 Feb; 62(1): 33–8PubMedCrossRefGoogle Scholar
  53. 53.
    Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992 Apr 2; 67(4): 417–23PubMedGoogle Scholar
  54. 54.
    Levine MN, Gent M, Hirsh J, et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism: a randomized trial in patients undergoing knee surgery. Arch Intern Med 1996; 156(8): 851–6PubMedCrossRefGoogle Scholar
  55. 55.
    Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001 Nov 20; 135(10): 858–69PubMedGoogle Scholar
  56. 56.
    Cohen AT, Bailey CS, Alikhan R, et al. Extended throm-boprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 2001 May; 85(5): 940–1PubMedGoogle Scholar
  57. 57.
    Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358(9275): 9–15PubMedCrossRefGoogle Scholar
  58. 58.
    Samama CM, Vray M, Barre J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162(19): 2191–6PubMedCrossRefGoogle Scholar
  59. 59.
    Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004 Sep; 2(9): 1573–80PubMedCrossRefGoogle Scholar
  60. 60.
    Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005 Jan; 3(1): 103–11PubMedCrossRefGoogle Scholar
  61. 61.
    Ho SJ, Brighton TA. Ximelagatran: direct thrombin inhibitor. Vasc Health Risk Manag 2006; 2(1): 49–58PubMedCrossRefGoogle Scholar
  62. 62.
    Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370(9591): 949–56PubMedCrossRefGoogle Scholar
  63. 63.
    Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 Nov; 5(11): 2178–85PubMedCrossRefGoogle Scholar
  64. 64.
    Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009 Jan; 24(1): 1–9PubMedCrossRefGoogle Scholar
  65. 65.
    Huo M, Eriksson B, Dahl O, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial [abstract no. 0564]. Haematologica 2010; 95 (Suppl. 2): 233Google Scholar
  66. 66.
    Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb Haemost 2009 Jan; 101(1): 77–85PubMedGoogle Scholar
  67. 67.
    Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010 Sep; 126(3): 175–82PubMedCrossRefGoogle Scholar
  68. 68.
    EMEA. CHMP assessment report for Pradaxa. Procedure no. EMEA/H/C/829, 2008 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-en6.pdf [Accessed 2010 May 1]
  69. 69.
    Hanf W, Duntze J, Hida H, et al. The implication of a direct antithrombine in the appearance of (serious) postoperative acute respiratory distress. Ann Fr Anesth Reanim 2009 Oct; 28(10): 885–8PubMedCrossRefGoogle Scholar
  70. 70.
    EMEA. Pradaxa: summary of product characteristics, 2008 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/pradaxa/emea-combined-h829en.pdf [Accessed 2010 May 1]
  71. 71.
    Zauderer B. Age-related changes in renal function. Crit Care Nurs Q 1996 Aug; 19(2): 34–40PubMedGoogle Scholar
  72. 72.
    Dahl OE, Kurth AA, Rosencher N, et al. Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years [poster ID 437]. In: American Society of Hematology, 2008 [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper2885.html [Accessed 2010 May 1]
  73. 73.
    Dahl OE, Kurth AA, Rosencher N, et al. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery [poster ID 981]. In: American Society of Hematology, 2008 [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper2917.html [Accessed 2010 May 1]
  74. 74.
    van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor —interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 Mar 29; 103(6): 1116–27PubMedCrossRefGoogle Scholar
  75. 75.
    Kapoor A, Chuang W, Radhakrishnan N, et al. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics 2010 Jul 1; 28(7): 521–38PubMedGoogle Scholar
  76. 76.
    Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health Technol Assess 2009 Sep; 13 Suppl. 2: 55–62PubMedGoogle Scholar
  77. 77.
    National Institute for Health and Clinical Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults, 2008 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12059/42032/42032.pdf [Accessed 2011 Jan 9]
  78. 78.
    National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital, 2010 [online]. Available from URL: http://guidance.nice.org.uk/CG92/Guidance/pdf/English [Accessed 2011 Jan 11]
  79. 79.
    McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27(10): 829–46PubMedCrossRefGoogle Scholar
  80. 80.
    Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009 Jan; 31(1): 194–212PubMedCrossRefGoogle Scholar
  81. 81.
    Wilke T, Neumann K, Klapper U, et al. Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals. Orthopade 2008 May; 37(5): 448–56PubMedCrossRefGoogle Scholar
  82. 82.
    Turpie A, Bauer K, Eriksson B, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003 Aug; 90(2): 364–6PubMedGoogle Scholar
  83. 83.
    Mesko JW, Brand RA, Iorio R, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 2001 Sep; 16(6): 679–88PubMedCrossRefGoogle Scholar
  84. 84.
    Mismetti P, Laporte S, Zufferey P, et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2004 Jul; 2(7): 1058–70PubMedCrossRefGoogle Scholar
  85. 85.
    Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 Jun 26; 358(26): 2765–75PubMedCrossRefGoogle Scholar
  86. 86.
    Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008 Jul 5; 372(9632): 31–9PubMedCrossRefGoogle Scholar
  87. 87.
    Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26; 358(26): 2776–86PubMedCrossRefGoogle Scholar
  88. 88.
    Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 May 16; 373(9676): 1673–80PubMedCrossRefGoogle Scholar
  89. 89.
    Huisman MV, Quinlan DJ, Dahl OE, et al. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010 Nov 1; 3(6): 652–60PubMedCrossRefGoogle Scholar
  90. 90.
    Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010 Mar 6; 375(9717): 807–15PubMedCrossRefGoogle Scholar
  91. 91.
    Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009 Aug 6; 361(6): 594–604PubMedCrossRefGoogle Scholar
  92. 92.
    Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010 Dec 23; 363(26): 2487–98PubMedCrossRefGoogle Scholar
  93. 93.
    Struijk-Mulder MC, Ettema HB, Verheyen CC, et al. Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. J Thromb Haemost 2010 Apr; 8(4): 678–83PubMedCrossRefGoogle Scholar
  94. 94.
    Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement: the influence of preventive intermittent calf compression and of surgical technique. Br J Surg 1983 Jan; 70(1): 17–9PubMedCrossRefGoogle Scholar
  95. 95.
    Samama CM, Clergue F, Barre J, et al. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Arar Study Group. Br J Anaesth 1997 Jun; 78(6): 660–5PubMedCrossRefGoogle Scholar
  96. 96.
    Francis CW, Pellegrini Jr VD, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA 1992 Jun 3; 267(21): 2911–5PubMedCrossRefGoogle Scholar
  97. 97.
    Silbersack Y, Taute BM, Hein W, et al. Prevention of deep-vein thrombosis after total hip and knee replacement: low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br 2004 Aug; 86(6): 809–12PubMedCrossRefGoogle Scholar
  98. 98.
    McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. BMJ 1980 Feb 23; 280(6213): 514–7PubMedCrossRefGoogle Scholar
  99. 99.
    Hull R, Delmore TJ, Hirsh J, et al. Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 1979; 16(1-2): 37–45PubMedCrossRefGoogle Scholar
  100. 100.
    Haas SB, Insall JN, Scuderi GR, et al. Pneumatic sequential-compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg Am 1990 Jan; 72(1): 27–31PubMedGoogle Scholar
  101. 101.
    Kaempffe FA, Lifeso RM, Meinking C. Intermittent pneumatic compression versus coumadin: prevention of deep vein thrombosis in lower-extremity total joint arthroplasty. Clin Orthop Relat Res 1991 Aug; 269: 89–97PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Department of MedicineMcMaster University and Thrombosis and Atherosclerosis Research InstituteHamiltonCanada
  2. 2.Department of HematologyKarolinska University Hospital and InstituteStockholmSweden
  3. 3.Department of MedicineMälar HospitalEskilstunaSweden

Personalised recommendations